» Authors » Jonathan W Kotula

Jonathan W Kotula

Explore the profile of Jonathan W Kotula including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 6
Citations 529
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Kurtz C, Millet Y, Puurunen M, Perreault M, Charbonneau M, Isabella V, et al.
Sci Transl Med . 2019 Jan; 11(475). PMID: 30651324
The intestine is a major source of systemic ammonia (NH); thus, capturing part of gut NH may mitigate disease symptoms in conditions of hyperammonemia such as urea cycle disorders and...
2.
Riglar D, Giessen T, Baym M, Kerns S, Niederhuber M, Bronson R, et al.
Nat Biotechnol . 2017 May; 35(7):653-658. PMID: 28553941
Bacteria can be engineered to function as diagnostics or therapeutics in the mammalian gut but commercial translation of technologies to accomplish this has been hindered by the susceptibility of synthetic...
3.
Myhrvold C, Kotula J, Hicks W, Conway N, Silver P
Nat Commun . 2015 Dec; 6:10039. PMID: 26615910
Microbial population growth is typically measured when cells can be directly observed, or when death is rare. However, neither of these conditions hold for the mammalian gut microbiota, and, therefore,...
4.
Kotula J, Sun J, Li M, Pratico E, Fereshteh M, Ahrens D, et al.
PLoS One . 2014 Apr; 9(4):e93441. PMID: 24736311
Unlabelled: β-arrestins, ubiquitous cellular scaffolding proteins that act as signaling mediators of numerous critical cellular pathways, are attractive therapeutic targets because they promote tumorigenesis in several tumor models. However, targeting...
5.
Kotula J, Kerns S, Shaket L, Siraj L, Collins J, Way J, et al.
Proc Natl Acad Sci U S A . 2014 Mar; 111(13):4838-43. PMID: 24639514
The mammalian gut is a dynamic community of symbiotic microbes that interact with the host to impact health, disease, and metabolism. We constructed engineered bacteria that survive in the mammalian...
6.
Kotula J, Pratico E, Ming X, Nakagawa O, Juliano R, Sullenger B
Nucleic Acid Ther . 2012 Jun; 22(3):187-95. PMID: 22703281
To reduce the adverse effects of cancer therapies and increase their efficacy, new delivery agents that specifically target cancer cells are needed. We and others have shown that aptamers can...